Evolva announces long-term commercial agreement with Cargill

EverSweet^TM next-generation stevia ingredient on track for 2018 launch

Evolva to establish global production hub in USA

Evolva announced that it has entered a major collaboration agreement with Cargill for the production and commercialisation of EverSweet^TM, the next-generation stevia sweetener. This product is on track for a 2018 launch, securing its first-mover advantage.

EverSweet^TM is a next-generation stevia sweetener that solves both the stevia taste and Reb M & Reb D scaleability challenges. EverSweet^TM is brewed to produce large quantities of the most sought-after sweetness ingredients found in the stevia leaf, Reb M and Reb D. The stevia leaf contains only minute quantities of these ingredients. EverSweet^TM also delivers better sweetness intensity, faster sweetness onset and improved sweetness quality – without the bitterness or off-note aftertaste common to existing stevia sweeteners. Evolva estimates the total addressable market to be worth around USD 4 billion.

Evolva will receive up to 30 % of the EverSweet^TM business, determined as a function of the strain efficiencies achieved. Evolva has the right to ask Cargill to support some of Evolva’s early cashflow commitments at a favourable interest rate, however under the new agreement Evolva will not receive any further milestone payments from Cargill.

EverSweet^TM next generation sweetener will initially be produced at a fermentation facility on Cargill’s Blair, Nebraska campus that will be retrofitted for this purpose. The facility will be operated by Cargill and additionally be used for the fermentation of other Evolva products. In parallel, Evolva will build and operate a new state-of-the-art bioprocessing facility on adjacent land leased from Cargill. This bioprocessing facility will manufacture Evolva products such as nootkatone and resveratrol and is expected to come online in 2019. Together, this integrated infrastructure will provide Evolva with a global hub for the production of high value specialty ingredients.

The production strategy provides a de-risked route for Evolva to establish its own low cost production of specialty ingredients through a collaboration with one of the world’s pre-eminent bioprocessing companies. Locating these operations in Blair, Nebraska also allows Evolva to leverage and access key resources such as Cargill’s centralised infrastructure, a skilled local labour pool, and a long-term supply of renewable resources from US farm inputs (corn, in particular). A number of world-class producers like Novozymes, Corbion and Evonik operate on the same Cargill campus in Blair.

Once completed, the Blair production facilities will play a pivotal role in accelerating the reduction of the cost-of-goods-sold for Evolva’s products, increasing the company’s long-term profitability. The facilities are expected to have sufficient capacity to generate an estimated USD 50 million-plus in annual product revenues for Evolva, over and above Evolva’s share of EverSweet^TM profits, and provide room for further expansion.

Over the next three years, principally in 2018 and 2019, Evolva expects to invest an estimated USD 60 million in the combined fermentation and bioprocessing facilities for EverSweet^TM and its other products. The recent CHF 30 million equity commitment from Yorkville serves as a foundation for this investment and Evolva expects to secure an additional project financing package of around CHF 30 million by end 2017, which will enable full execution of the plans.